Peer Reviewed
Complementary medicine update

Lipoic acid for Alzheimer’s disease

Gerald Münch, Lynne Shinto, Annette Maczurek
Abstract
Two open trials in Germany and a pilot double-blind, randomised placebo-controlled trial in the USA might suggest a long-term substantial benefit for lipoic acid in treating Alzheimer’s disease.
Key Points

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication skills and ability to perform activities of daily living. It affects up to 40% of people over 85 years of age. Despite extensive research into the pathogenesis of AD, a neuroprotective treatment is still unavailable for clinical use – particularly for the early stages of disease.

    Alpha lipoic acid (LA), an antioxidant that has been registered as a medicine in Germany for diabetic neuropathy since 1966, might offer benefits for patients with AD.

Purchase the PDF version of this article
Already a subscriber?